A Biodegradable, Sustained-Released, Prednisolone Acetate Microfilm Drug Delivery System Effectively Prolongs Corneal Allograft Survival in the Rat Keratoplasty Model
Frequent and long-term use of topical corticosteroids after corneal transplantation is necessary to prevent graft rejection. However, it relies heavily on patient compliance, and sustained therapeutic drug levels are often not achieved with administration of topical eye drops. A biodegradable drug delivery system with a controlled and sustained drug release may circumvent these limitations. In this study, we investigated the efficacy of a prednisolone acetate (PA)-loaded poly (d,l-lactide-co-ε-caprolactone) (PLC) microfilm drug delivery system on promoting the survival of allogeneic grafts after penetrating keratoplasty (PK) using a rat model. The drug release profiles of the microfilms were characterized (group 1). Subsequently, forty-eight PK were performed in four experimental groups: syngeneic control grafts (group 2), allogeneic control grafts (group 3), allogeneic grafts with subconjunctivally-implanted PA microfilm (group 4), and allogeneic grafts with PA eye drops (group 5; n = 12 in each). PA-loaded microfilm achieved a sustained and steady release at a rate of 0.006–0.009 mg/day, with a consistent aqueous drug concentration of 207–209 ng/ml. The mean survival days was >28 days in group 2, 9.9±0.8 days in group 3, 26.8±2.7 days in group 4, and 26.4±3.4 days in group 5 (P = 0.023 and P = 0.027 compared with group 3). Statistically significant decrease in CD4+, CD163+, CD 25+, and CD54+ cell infiltration was observed in group 4 and group 5 compared with group 3 (P<0.001). There was no significant difference in the mean survival and immunohistochemical analysis between group 4 and group 5. These results showed that sustained PA-loaded microfilm effectively prolongs corneal allograft survival. It is as effective as conventional PA eye drops, providing a promising clinically applicable alternative for patients undergoing corneal transplantation.
References
[1]
Tan DT, Dart JK, Holland EJ, Kinoshita S (2012) Corneal transplantation. Lancet 379: 1749–1761.
[2]
Eye Banking Statistical Report Eye Bank Association of America 2011. Available: http://www.restoresight.org. Accessed 2012 Nov 12.
[3]
Tan DT, Janardhanan P, Zhou H, Chan YH, Htoon HM, et al. (2008) Penetrating keratoplasty in Asian eyes: the Singapore Corneal Transplant Study. Ophthalmology 115: 975–982.e1.
[4]
Shimazaki J, Iseda A, Satake Y, Shimazaki-Den S (2012) Efficacy and safety of long-term corticosteroid eye drops after penetrating keratoplasty: a prospective, randomized, clinical trial. Ophthalmology 119: 668–673.
[5]
Panda A, Vanathi M, Kumar A, Dash Y, Priya S (2007) Corneal graft rejection. Surv Ophthalmol 52: 375–396.
[6]
Sangwan VS, Ramamurthy B, Shah U, Garg P, Sridhar MS, et al. (2005) Outcome of corneal transplant rejection: a 10-year study. Clin Experiment Ophthalmol 33: 623–627.
[7]
Prabhu SS, Kaakeh R, Sugar A, Smith DG, Shtein RM (2013) Comparative Cost-Effectiveness Analysis of Descemet Stripping Automated Endothelial Keratoplasty versus Penetrating Keratoplasty in the United States. Am J Ophthalmol 155: 45–53.
[8]
Bose S, Ang M, Mehta JS, Tan DT, Finkelstein E (2013) Cost-Effectiveness of Descemet’s Stripping Endothelial Keratoplasty versus Penetrating Keratoplasty. Ophthalmology 120: 464–470.
[9]
Santos LN, de Moura LR, Fernandes BF, Cheema DP, Burnier MN Jr (2011) Histopathological study of delayed regraft after corneal graft failure. Cornea 30: 167–170.
[10]
Hill JC (1994) Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology 101: 128–133.
[11]
Nguyen P, Barte F, Shinada S, Yiu SC (2010) Management of Corneal Graft Rejection - A Case Series Report and Review of the Literature. J Clin Exp Ophthalmol 1. pii: 1000103.
[12]
Bersudsky V, Blum-Hareuveni T, Rehany U, Rumelt S (2001) The profile of repeated corneal transplantation. Ophthalmology 108: 461–469.
[13]
Cho YK, Uehara H, Young JR, Tyagi P, Kompella UB, et al. (2012) Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci 53: 2328–2336.
[14]
Buxton JN, Apisson JG, Hoeffle FB (1969) Corticosteroids in 100 keratoplasties. Am J Ophthalmol 67: 46–51.
[15]
Koay PY, Lee WH, Figueiredo FC (2005) Opinions on risk factor and management of corneal graft rejection in the United Kingdom. Cornea 24: 292–296.
[16]
Olthoff C, Schouten JvdB, Websers CA (2005) Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: An evidence-based review. Ophthalmology 112: 953–961.
[17]
Liu YC, Wong TT, Mehta JS (2013) Intraocular lens as a drug delivery reservoir. Curr Opin Ophthalmol 24: 53–59.
[18]
Barcia E, Herrero-Vanrell R, Díez A, Alvarez-Santiago C, López I, et al. (2009) Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Exp Eye Res 89: 238–245.
[19]
Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, et al. (2003) Controlled delivery of the anti-VEGF aptamer EYE001with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci 44: 290–299.
[20]
Peng Y, Ang M, Foo S, Lee WS, Ma Z, et al. (2011) Biocompatibility and biodegradation studies of subconjunctival implants in rabbit eyes. PLoS One 6: e22507.
[21]
de Rojas Silva MV, Rodríguez-Ares MT, Sánchez-Salorio M, Lamas Díaz MJ, Cuevas Alvarez J, et al. (1999) Efficacy of subconjunctival cyclosporin-containing microspheres on keratoplasty rejection in the rabbit. Graefes Arch Clin Exp Ophthalmol 237: 840–847.
[22]
Natarajan JV, Ang M, Darwitan A, Chattopadhyay S, Wong TT, et al. (2012) Nanomedicine for glaucoma: liposomes provide sustained release of lantanoprost in the eye. Int J Nanomedicine 7: 123–131.
[23]
Joachim Loo SC, Jason Tan WL, Khoa SM, Chia NK, Venkatraman S, et al. (2008) Hydrolytic degradation characteristics of irradiated multi-layered PLGA films. Int J Pharm 360: 228–230.
[24]
Steele TW, Huang CL, Widjaja E, Boey FY, Loo JS, et al. (2011) The effect of polyethylene glycol structure on paclitaxel drug release and mechanical properties of PLGA thin films. Acta Biomater 7: 1973–1983.
[25]
Zhu Y, Chian KS, Chan-Park MB, Mhaisalkar PS, Ratner BD (2006) Protein bonding on biodegradable poly(L-lactide-co-caprolactone) membrane for esophageal tissue engineering. Biomaterials 27: 68–78.
Lu XL, Cai W, Gao ZY (2008) Shape-memory behaviors of biodegradable poly(L-lactide-co-？-caprolactone) copolymers. J Appl Polym Sci 108: 1109–1115.
[28]
Ang M, Yan P, Zhen M, Foo S, Venkatraman SS, et al. (2011) Evaluation of sustained release of PLC-loaded prednisolone acetate microfilm on postoperative inflammation in an experimental model of glaucoma filtration surgery. Curr Eye Res 36: 1123–1128.
[29]
Liu YC, Peng Y, Lwin NC, Wong TT, Venkatraman SS, et al. (2013) Optimization of Subconjunctival Biodegradable Microfilms for Sustained Drug Delivery to the Anterior Segment in a Small Animal Model. Invest Ophthalmol Vis Sci 54: 2607–2615.
[30]
Lao LL, Venkatraman SS, Peppas NA (2008) Modeling of drug release from biodegradable polymer blends. Eur J Pharm Biopharm 70: 796–803.
[31]
Zhang EP, Schründer S, Hoffmann F (1996) Orthotopic corneal transplantation in the mouse–a new surgical technique with minimal endothelial cell loss. Graefes Arch Clin Exp Ophthalmol 234: 714–719.
[32]
Pan Z, Chen Y, Zhang W, Jie Y, Li N, et al. (2003) Rat corneal allograft survival prolonged by the superantigen staphylococcal enterotoxin B. Invest Ophthalmol Vis Sci. 44: 3346–3351.
[33]
Munger RJ (2002) Veterinary ophthalmology in laboratory animal studies. Vet Ophthalmol 5: 167–175.
[34]
Lee SS, Hughes P, Ross AD, Robinson MR (2010) Biodegradable Implants for Sustained Drug Release in the Eye. Pharm Res 27: 2043–2053.
[35]
Nicholson BP, Singh RP, Sears JE, Lowder CY, Kaiser PK (2012) Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery. Am J Ophthalmol 154: 969–973.e1.
[36]
Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM (2009) Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 29: 46–51.
[37]
Xie L, Shi W, Wang Z, Bei J, Wang S (2001) Prolongation of corneal allograft survival using cyclosporine in a polylactide-co-glycolide polymer. Cornea 20: 748–752.
[38]
Shi W, Gao H, Xie L, Wang S (2006) Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci 47: 3339–3344.
[39]
Shi W, Liu T, Xie L, Wang S (2005) FK506 in a biodegradable glycolide-co-clatide-co-caprolactone polymer for prolongation of corneal allograft survival. Curr Eye Res 30: 969–976.
[40]
Kagaya F, Usui T, Kamiya K, Ishii Y, Tanaka S, et al. (2002) Intraocular dexamethasone delivery system for corneal transplantation in an animal model. Cornea 21: 200–202.
[41]
Tan DT, Chee SP, Lim L, Theng J, Van Ede M (2001) Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery : anterior versus posterior placement of two Surodex in the eye. Ophthalmology 108: 2172–2181.
[42]
Rodríguez FJ, Gómez N, Perego G, Navarro X (1999) Highly permeable polylactide-caprolactone nerve guides enhance peripheral nerve regeneration through long gaps. Biomaterials 20: 1489–1500.
[43]
Honda M, Morikawa N, Hata K, Yada T, Morita S, et al. (2003) Rat costochondral cell characteristics on poly (L-lactide-co-epsilon-caprolactone) scaffolds. Biomaterials 24: 3511–3519.
[44]
Cho HH, Han DW, Matsumura K, Tsutsumi S, Hyon SH (2008) The behavior of vascular smooth muscle cells and platelets onto epigallocatechin gallate-releasing poly(l-lactide-co-epsilon-caprolactone) as stent-coating materials. Biomaterials 29: 884–893.
[45]
Awan MA, Agarwal PK, Watson DG, McGhee CN, Dutton GN (2009) Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol 93: 708–713.
[46]
Lawrence MS, Miller JW (2004) Ocular tissue permeabilities. Int Ophthalmol Clin 44: 53–61.
[47]
Gaudana R, Jwala J, Boddu SH, Mitra AK (2009) Recent perspectives in ocular drug delivery. Pharm Res 26: 1197–1216.
McGhee CN, Watson DG, Midgley JM, Noble MJ, Dutton GN, et al. (1990) Penetration of synthetic corticosteroids into human aqueous humour. Eye (Lond) 4: 526–530.
[50]
Zhang W, Prausnitz MR, Edwards A (2004) Model of transient drug diffusion across cornea. J Control Release 99: 241–258.
[51]
Mayer K, Birnbaum F, Reinhard T, Reis A, Braunstein S, et al. (2004) FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. Br J Ophthalmol 88: 915–919.
[52]
Katami M (1995) The mechanisms of corneal graft failure in the rat. Eye (Lond) 9: 197–207.
[53]
Bertelmann E, Jaroszewski J, Pleyer U (2002) Corneal allograft rejection: current understanding. 2. Clinical implications. Ophthalmologica 216: 2–12.
[54]
Yamagami S, Tsuru T, Isobe M, Obata H, Suzuki J (1996) The role of cell adhesion molecules in allograft rejection after penetrating keratoplasty in mice. Clinical and immunohistochemical study. Graefes Arch Clin Exp Ophthalmol 234: 382–387.
[55]
Coster DJ, Jessup CF, Williams KA (2010) Mechanisms of corneal allograft rejection and the development of new therapies. In: Reinhard T, Larkin F, editors. Essentials in Ophthalmology. Cornea and external eye disease. Springer, Germany, 13–23.
